319 related articles for article (PubMed ID: 31637485)
1. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.
Liu L; Jia M; Sun L; Tian W; Tang P; Jiang Z
Clin Exp Med; 2021 Nov; 21(4):537-543. PubMed ID: 33866494
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
5. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies.
Wan Z; Han B
Aging (Albany NY); 2021 Mar; 13(8):11120-11134. PubMed ID: 33818418
[TBL] [Abstract][Full Text] [Related]
6. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
7. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
9. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
[TBL] [Abstract][Full Text] [Related]
13. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
14. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Komrokji RS
Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
[TBL] [Abstract][Full Text] [Related]
15. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
16. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
[TBL] [Abstract][Full Text] [Related]
17. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
Du M; Zhou F; Jin R; Hu Y; Mei H
Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
Jabbour E; Mathisen MS; Garcia-Manero G; Champlin R; Popat U; Khouri I; Giralt S; Kadia T; Chen J; Pierce S; Koca E; Daver N; Tanaka M; Rondon G; Oran B; Parmar S; Kantarjian H; de Lima M
Am J Hematol; 2013 Mar; 88(3):198-200. PubMed ID: 23345254
[TBL] [Abstract][Full Text] [Related]
20. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]